Fluzone Trivalent
Phase 1Biologic
Fluzone Trivalent is one of 37 biologic programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Cutaneous Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Keytruda
Merck & Co.Phase 2
Intismeran Autogene
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
Fabhalta
RegeneronPhase 2
Tecentriq
RochePhase 2
Jakafi
IncytePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Opdualag
Bristol-Myers SquibbPhase 2
Erbitux
IImclone
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cutaneous Squamous Cell Carcinoma1 trial
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Recruiting·—·Phase 1·NCT06664151·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluzone Trivalent. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- DDana-Farber Cancer Institute